Psoriasis can be a real pain—literally. It’s no walk in the park, especially when those pesky plaques show up to ruin the day. Enter high-dose risankizumab, the superhero we didn’t know we needed.
Standard dosing is 150 mg, and it’s given at weeks 0, 4, and then every 12 weeks. But those who are tired of waiting? They might want to contemplate going big or going home with 300 mg or even 600 mg doses at weeks 0, 4, and 16.
In clinical trials, high-dose risankizumab has shown some serious promise. By week 12, patients have seen a mean PASI improvement of over 80%. That’s impressive. And it works faster than standard doses, with visible efficacy kicking in as early as week 4. Who wouldn’t want clearer skin in a month?
High-dose risankizumab delivers impressive results, with over 80% PASI improvement by week 12 and visible effects in just four weeks.
In the high-dose trials, an average of 58% of participants reported clearer skin just four weeks after their first dose. Additionally, this approach has led to significant long-term reduction in disease severity, making it a compelling option for those seeking rapid relief.
What’s the catch? Well, there really isn’t one. The safety profile is pretty solid, with no nasty surprises popping up. One serious adverse event in a 300 mg arm doesn’t exactly scream danger.
And over six years, risankizumab has proven to be well-tolerated.
But let’s talk durability. High-dose risankizumab targets those stubborn resident memory cells, ensuring that clear skin lasts. Not just for a few weeks, either. We’re talking about sustained PASI 90 results through two years of continuous treatment. That’s a major win.
High response rates are achieved not just on the body, but in those tricky areas like nails and scalp. If you’re tired of battling psoriasis, high-dose risankizumab could be the rapid response you’ve been longing for.
